Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 1998

View Archived Issues

Aryl C-glycosides as selectin inhibitors jointly developed by Sankyo, Glycomed

SmithKline Beecham describes new cannabinoid receptor agonists

Lipid-lowering ACAT inhibitors claimed in patent literature by Yakult Honsha

New sigma-receptor ligands presented by Sumitomo

Inhibitors of cell adhesion with antiinflammatory activity developed at Japan Energy

Merck's new ET receptor antagonists

CardioGenesis, Eclipse Surgical Technologies to merge

Step taken toward European protection for AltaRex's fundamental technology platform

Another merger announced: Cell Pathways acquires Tseng Labs

Bayer announces setback in AD drug development

NIAID to sponsor trials of female-controlled topical microbicide; FDA gives green light to study

Angiotech study of micellar paclitaxel in MS well under way

Irreversible inactivators of EGF receptor TK hold promise as antitumor agents

Nortran advances development of novel cough remedy

Significant antiinflammatory activity seen with loteprednol etabonate in cataract surgery setting

Chinese researchers report that synthetic calcium antagonist improves memory dysfunction

Licensing opportunity from NIH: G-protein-coupled receptor antagonists

Licensing opportunity from the NIH: method of inhibiting HGF/SF cleavage, activation

Millennium succeeds in identifying sixth antibacterial target in Wyeth-Ayerst alliance

Highly potent H3 receptor antagonist with potential therapeutic use

Dutch research group focuses attention on adenosine A3 receptor ligands

Ribozyme oligonucleotides against apo(a) as novel therapeutic strategy for cardiovascular diseases

Reduction in the incidence of dementia obtained with antihypertensive treatment

Eisai to collaborate with Toyama in development, marketing of DMARD

Pfizer and Hoechst Marion Roussel reach agreement for worldwide development of inhaled insulin

Zadaxin plus famciclovir provides surprising synergistic efficacy against HBV

Enzyme formulation for pancreatic insufficiency enters preclinical development at Altus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...